Four proven clinical interventions “should constitute a set of ‘universal precautions’ that clinicians and health systems could implement to reduce opioid overdose deaths among at-risk
Second-generation antipsychotic agents can be useful in patients with treatment-resistant depression when patients and clinicians use a shared decision-making approach, write the authors of a
The second-generation antipsychotic agent (SGA) cariprazine, a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist, was effective for reducing depressive symptoms in a trial of adults with
Beta-blocker (BB) therapy is associated with significantly lower short- and long-term mortality rates among all patients with heart failure with reduced ejection fraction (HFrEF), including
FDA last week approved velmanase alfa (Lamzede), the first enzyme replacement therapy approved in the U.S. for the treatment of non-central nervous system manifestations of alpha-mannosidosis,
Compared with argatroban alone in patients with acute ischemic stroke (AIS), argatroban plus intravenous alteplase did not significantly improve the likelihood of excellent functional outcome
Among individuals with smoking exposure with and without COPD, a study identifies “risk factors for suicide/overdose … that emphasize the subjective experience of illness over
Antidepressants were significantly effective for treating pain in adults in about one-quarter of the comparisons included in an overview of systematic reviews of placebo-controlled trials.
Comorbid posttraumatic stress disorder (PTSD) and substance-use disorders should be managed using a combination approach, including alcohol-targeted pharmacotherapies and trauma-focused behavioral therapies that lead to
The gap between opioid use disorder and buprenorphine dispensing trends to youth aged 19 years or younger indicated that many individuals are receiving the help